Imatin 400 mg (Tablet)
Unit Price: ৳ 400.00 (3 x 10: ৳ 12,000.00)
Strip Price: ৳ 4,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Imatinib mesylate |
| Company | Techno drugs ltd |
| Also available as |
Usage and Administration
- Adults with Ph+ CML CP: 400 mg/day
- Adults with Ph+ CML AP or BC: 600 mg/day
- Pediatrics with Ph+ CML CP: 340 mg/m2/day
- Adults with Ph+ ALL: 600 mg/day
- Pediatrics with Ph+ ALL: 340 mg/m2/day
- Adults with MDS/MPD: 400 mg/day
- Adults with ASM: 100 mg/day or 400 mg/day
- Adults with HES/CEL: 100 mg/day or 400 mg/day
- Adults with DFSP: 800 mg/day
- Adults with metastatic and/or unresectable GIST: 400 mg/day
- Adjuvant treatment of adults with GIST: 400 mg/day
- Patients with mild to moderate hepatic impairment: 400 mg/day
- Patients with severe hepatic impairment: 300 mg/day
- Dosage taken with a meal and a large glass of water
- Imatinib can be dissolved in water or apple juice for patients having difficulty swallowing
Pharmacological Action
- It is a small molecule protein-tyrosine kinase inhibitor
- Potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK)
- Inhibits several receptor TKs: Kit, DDR1 and DDR2, CSF-1R, PDGFR-alpha and beta
Metabolism and Excretion
- Imatinib is well absorbed after oral administration with Cmax achieved within 2-4 hours post-dose
- Mean absolute bioavailability is 98%
- CYP3A4 is the major enzyme responsible for metabolism of Imatinib
- Imatinib elimination is predominately in the feces, mostly as metabolites
Interactions
- Concomitant administration of Imatinib and strong CYP3A4 inducers may reduce total exposure
- Concomitant administration of Imatinib and strong CYP3A4 inhibitors may result in a significant Imatinib exposure increase
- Imatinib will increase plasma concentration of CYP3A4 metabolized drugs
- Use caution when administering Imatinib with CYP2D6 substrates that have a narrow therapeutic window
Side Effects
- Fluid Retention and Edema
- Hematologic Toxicity
- Congestive Heart Failure and Left Ventricular Dysfunction
- Hepatotoxicity
- Hemorrhage
- Gastrointestinal Disorders
- Hypereosinophilic Cardiac Toxicity
- Dermatologic Toxicities
- Hypothyroidism
- Growth Retardation in Children and Adolescents
- Tumor Lysis Syndrome
- Impairments Related to Driving and Using Machinery
- Renal Toxicity
Pregnancy & Lactation
- Women of childbearing potential must use effective contraception during treatment and for at least 15 days after stopping treatment
- Imatinib should not be used during pregnancy unless clearly necessary
- There is limited information on Imatinib distribution in human milk
Precautions & Warnings
- Edema and severe fluid retention have occurred
- Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, have occurred
- Severe congestive heart failure and left ventricular dysfunction have been reported
- Severe hepatotoxicity, including fatalities may occur
- Grade 3/4 hemorrhage has been reported in clinical studies
- Bullous dermatologic reactions have been reported
- Fetal harm can occur when administered to a pregnant woman
- Growth retardation occurring in children and pre-adolescents receiving Imatinib has been reported
- Tumor Lysis Syndrome has been reported
- Reports of motor vehicle accidents have been received in patients receiving Imatinib
- Renal Toxicity has been reported
Overdose Effects
- Experience with doses higher than the recommended therapeutic dose is limited
- In the event of overdose, the patient should be observed and appropriate supportive treatment given
Therapeutic Class
Targeted Cancer Therapy, Tyrosine Kinase Inhibitor
Storage Conditions
Store below 30°C, in a cool and dry place